WeightWatchers' new GLP-1 program offers daily nutritional and activity targets, recommended foods, recipes, food and activity tracking, a digital community, virtual workshops and access to coaches 24/7.
Prescriptions for GLP-1s are soaring, but fewer than a third of people prescribed the costly drugs will continue taking them one year later without personalized support. Without the expert guidance of a registered dietitian, you risk not achieving the significant clinical benefits these drugs offer and forfeiting the potential for sustainable, transformative health outcomes.
Meevo offers an all-in-one solution for managing salon and spa employees. From scheduling and time tracking to payroll and promotions, Meevo streamlines operations and supports growth.
Novo Nordisk's planned expansion will more than double the footprint of its France production site, bringing new capacity for manfacturing GLP-1 drugs for metabolic conditions. The location is already one of the company’s largest for making diabetes products.
Carmot Therapeutics isn’t the first company targeting both the GLP-1 and GIP receptors to treat metabolic diseases. But the company contends that biased signaling—activating certain pathways but not others—is key to setting its drugs apart from others in the same class.
Just 37% of employees trust their insurer to suggest high-quality care regardless of cost, while 53% trust their employer with their health, according to a survey released by Included Health.
AstraZeneca gains global rights to an oral GLP-1 agonist on track to reach Phase 2 testing in 2024. Under China-based Eccogene, the small molecule’s Phase 1 data show reductions in glucose and body weight.
This eBook provides actionable strategies, real-world best practices to help payers stay ahead in a value-based care environment.
Walgreens is seeing “an enormous amount of demand” for injectable weight loss drugs, its president of U.S. healthcare said during the Reuters Total Health conference in Chicago. He declared that the healthcare industry needs to come up with a reimbursement model “that correctly compensates pharmacists and others” to administer these drugs. In his view, reimbursement hasn't caught up with the demand.
Eli Lilly weight management drug Zepbound landed its much anticipated FDA approval. The new Lilly product is in the same drug class as Novo Nordisk weight medication Wegovy, but it offers an additional mechanism of action and costs less.
People with obesity should be offered a range of suitable treatments as well: behavioral, nutrition, exercise, medication and surgery, through a coordinated and holistic approach under one roof, with a care coordinator. Like cancer, obesity is a heterogeneous disease and recommendations and responses to all treatment modalities will be heterogeneous as well.
Weight loss company Calibrate — which sells a program combining GLP-1 drugs with personalized metabolic health coaching — announced a legal restructuring of its business. The startup, which recently had two major rounds of layoffs, has struggled amid GLP-1 drug shortages and mounting user complaints.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Obesity management solutions offer a middle path for patients and providers. They help mitigate cost trends for payers and employers while maintaining access and providing equitable care to members and employees.
Noom is now offering Noom Med to employers. The program is intended for patients who need more clinical support in their weight loss journey. It offers access to a clinician and medications, including GLP-1s.
A study testing Novo Nordisk's semaglutide in chronic kidney disease is ending early after an interim analysis met efficacy goals. Detailed results are not yet available, but they could support expanding use of the GLP-1 agonist, which is far and away Novo Nordisk’s top-selling product.
Healthcare-focused market research firm Trilliant Health published a report detailing the 10 most significant economic trends affecting U.S. healthcare stakeholders in 2023. Some of the main ideas covered in the report included Americans’ worsening physical and mental health, the industry’s shift away from traditional care pathways, and the way patients' decision making is becoming increasingly driven by consumerism.
A new PitchBook report listed several predictions for digital health companies in regards to weight loss drugs, including the potential for new weight loss startups and possible challenges for existing nutrition companies.